Upcoming
Innovations and good practices in the health sector
on
8 November 2022
. Моля да презаредите таба на браузъра си ако екранът ви не се обнови автоматично до няколко секунди.
Dr. Ivan Madjarov was elected chairman of the professional organization of the 68th regular reporting and election fair of the BMA in June 2018.
Prior to heading the Bulgarian Medical Association, he was the manager of the Pulmed Hospital in Plovdiv and was the chairman of the board of the Bulgarian Hospital Association.
From 2013 to 2014 he was the director of RHIF Plovdiv.
From 2008 to 2013 he was the manager of Parvomay Hospital EOOD. From 1994 to 2008 he was an intern in the ENT department at the Plovdiv Hospital in Plovdiv.
Dr. Ivan Madjarov graduated from the Medical University - Plovdiv. He has a degree in "Ear, Nose and Throat Diseases" and a Master's degree in Health Management.
Dr. Krasimira Chemishanska is a business leader in the pharmaceutical industry with more than 20 years of experience in the Bulgarian market and part of the AstraZeneca management team.
She graduated medicine at the Medical University in Sofia and worked as a research associate in the field of clinical immunology for two years. Following the challenges of her professional career, she received a degree in marketing, an MBA in General Management from City University Seattle, and a master's degree in management from the International Business School.
From 1994 to 2009, she held various management positions in multinational innovative pharmaceutical companies, as she was a long-time Marketing Director and Member of the Board of Directors of AstraZeneca.
In 2009 she entered the role of Executive Director of Amgen Bulgaria, opening a branch of one of the largest biotechnology companies in the world in our country and developing the organization and the business on local soil to this day.
Since 2011 she has been a member of the Board of Directors of AmCham, and in 2015 she was elected President of the Chamber - a position she held until the beginning of 2019.
Since 2013, Dr. Chemishanska has been a member of the board of ARPharM, and from 2019 to the beginning of 2021 she headed the Association of Research Pharmaceutical Manufacturers in Bulgaria as Chairman of the Board. Dr. Chemishanska is currently Vice President of ARPharM. She is also a longtime member of the BBLF and a lecturer in the Master Classes of the Pharmaceutical Industry Forum.
Dr. Chemishanska is also an honorary member of the Council of the European Business Community and winner of the Golden Seal Award for Innovative Management and Social Responsibility. In 2013 she received the prestigious "Certificate of Appreciation" from the US Department of Commerce for her contribution to the development of bilateral trade and investment in healthcare between the United States and Bulgaria.
Director Association of Research-based Pharmaceutical Manufacturers Bulgaria (ARPharM Bulgaria)
Deyan Denev is heading the Association of Research-based Pharmaceutical Manufacturers in Bulgaria since October 2003. He has a legal education from Sofia University and is an expert in pharmaceutical legislation and pharmaceutical policy. As Director of the association he is leading the advocacy activities of R&D pharmaceutical industry in Bulgaria on key issues regarding pharmaceutical policy, regulatory environment, intellectual property, pharmaceutical market development.
He was a member of the Supervisory Board of the National Health Insurance Fund on behalf of the Confederation of Employers and Industrialists in Bulgaria from January 2014 to January 2015.
Between 2008 and 2013 he was a representative of the pharmaceutical industry in the Transparency Commission, which is an appeal body for all piecing and reimbursement decisions in Bulgaria. He is a co-chair of the Central and Eastern European Task Force of EFPIA (European Federation of Pharmaceutical Industries and Associations).
Mr. Denev is a member of the Managing Board of the Bulgarian Medicines Verification Organization. In 2019 and 2021 he chairs the organization.
Lawyer Maria Sharkova is a managing partner in Sharkova & Partners Law Firm. The company's team has many years of experience in consulting medical institutions, non-governmental organizations and patients and successfully leads cases in the field of healthcare. Lawyer Sharkova specializes in the United States and has worked as an intern in the Legal Program of the Centers for Disease Control (CDC) in Atlanta. In the field of medical law, there are many short-term trainings in the Netherlands, Spain and other European countries, and recently acquired the right to train for the Council of Europe platform HELP.
Andrija Tomovic is Country president, Novartis Bulgaria since 01 October 2022 and previously had been conducting the role of Oncology General Manager for Bulgaria (BG) and North Macedonia (NM) since 2021Q1. Before joining the Novartis BG & NM team Andrija held various cross-functional positions of increasing responsibilities within Novartis in Rotkreuz (Switzerland) - Swiss Oncology Business Unit, Origgio/Milan (Italy) – Oncology Region Europe, Basel (Switzerland) - Novartis Research and Development organizations, including Novartis Corporate, Group Finance / Investor Relations also in Basel (Switzerland).
Andrija holds a BSc in Mathematics and a MSc in Computer Science, a PhD Bioinformatics from the University of Basel and an Executive MBA from SBS/Zürich. Andrija is a Certified Financial Analyst (CFA) charterholder and has authored ~17 peer-reviewed and highly-cited manuscripts on topics surrounding bioinformatics, machine learning/artificial intelligence/statistics, genomics, clinical genetic studies, and the pharma stock market.
Economist at the Institute for Market Economy Foundation
Deyan Lakovski
Balkans cluster director at AstraZeneca
Dejan Lakovski has solid business experience within the pharmaceutical industry for more than 20 years and over the past 12 years he has held various Managing Director positions in different companies. Since 2021, he is Cluster Country Director, Balkans at AstraZeneca, which encompasses 9 countries and more than 250 employees. With his strong background in managing multicultural and cross-functional teams, in his current role Dejan is committed to building a diverse, highly engaged and patient-focused team that is committed to the company’s values and ambitious sustainability agenda. Before joining AstraZeneca, he was General Manager at STADA Bulgaria responsible for Croatian and Slovenian market. Prior that Dejan was growing his career in Sandoz, Novartis and Roche and combining both commercial and business development functions.
Dejan is a Medical Doctor and has an MBA in Economics from the University of Skopje.
Dr. Kiril Nikolchev is Co-Founder and Chairman of Hub for Health. Before that, he was the general manager for Bulgaria of the biopharmaceutical company AbbVie from 2013 and worked at Abbott Laboratories, where he passed through all hierarchical levels - from product to general manager. Prior to joining Abbott, he worked at DePuy, Johnson & Johnson and Solvay Pharma. In 1999, he graduated from the Medical University of Varna, and in 2012 he obtained a master's degree in business administration from the City University of Seattle.
Dr. Kiril Nikolchev
Co-Founder and Chairman of Hub for Health
Elitsa Beyska
Project Manager at the European Innovation Council Accelerator, Executive Agency for Small and Medium Enterprises of the European Commission, Brussels
Elitsa Beyska
Project Manager at the European Innovation Council Accelerator, Executive Agency for Small and Medium Enterprises of the European Commission, Brussels
He graduated in Robotics, at the Faculty of Automation, TU-Sofia in 1997. He has been working as a service engineer of laboratory equipment of Ciba Corning and Shimadzu at Perfect Medica Ltd. In 1999 he created the first in Bulgaria Laboratory Information System (LIS iLab) through his company SKYWARE Group Ltd. LIS iLab for the first time in Bulgaria used material barcoding and LIS-device connection. In 2001 he implemented the first online lab results. In 2004 he was the main developer of the first electronic reporting system of the National Health Insurance Fund at Manro Ltd. He works actively in LIS and HIS integration projects, successfully integrating six different HIS into LIS iLab. In March 2006, the Arenal electronic referral system was developed and put into operation, through which a two-way connection between doctors and laboratories is carried out at national level.
Можете да следвате нашите автори или важните за вас теми, само ако сте регистриран потребител.
Влезте в профила си или създайте нов.
С използването на сайта вие приемате, че използваме „бисквитки" за подобряване на преживяването, персонализиране на съдържанието и рекламите, и анализиране на трафика. Вижте нашата
политика за бисквитките
и
декларацията за поверителност.